Dear HIFA members,
Cochrane launched today its COVID-19 Study Register - a register with primary research studies on COVID-19. https://covid-19.cochrane.org/
The aim of the register is to support rapid evidence synthesis by all systematic review producers, including Cochrane's work on Rapid Reviews in response to COVID-19. The register helps systematic reviewers prioritize topics, identify available evidence, and produce urgently needed reviews for front-line health professionals, public health policymakers, and research teams developing new therapeutic, diagnostic, and preventive interventions for COVID-19.
The new COVID-19 Study Register will be continually updated with human studies on COVID-19. More background information about the register can be found here: https://community.cochrane.org/about-covid-19-study-register
Please direct any questions or comments about Cochrane's COVID-19 Study Register to firstname.lastname@example.org
With best wishes,
Sylvia de Haan
Head of External Affairs & Geographic Groups’ Support
Chief Executive’s Office
Cochrane Central Executive
E email@example.com T +31 6 24489499 S sylviadehaan31
Trusted evidence. Informed decisions. Better health.
The Cochrane Collaboration. Registered in England as a company limited by guarantee No. 03044323 Charity Number 1045921. VAT registration number GB 718 2127 49. Registered office: St Albans House, 57-59 Haymarket, London SW1Y 4QX United Kingdom
HIFA profile: Sylvia de Haan is Partnerships Coordinator at Cochrane, and is based in the Netherlands. Email address: sdehaan AT cochrane.org